UK markets close in 3 hours 32 minutes

Kyowa Kirin Co., Ltd. (KYKOF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
27.000.00 (0.00%)
At close: 9:35AM EST

Kyowa Kirin Co., Ltd.

Otemachi Financial City Grand Cube
1-9-2, Otemachi Chiyoda-ku
Tokyo 100-0004
Japan
81 3 5205 7200
http://www.kyowakirin.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees5,267

Key executives

NameTitlePayExercisedYear born
Mr. Masashi MiyamotoPres, CEO & Exec. DirectorN/AN/A1959
Mr. Motohiko KawaguchiDirector of Fin. Department & Exec. OfficerN/AN/AN/A
Mr. Kenya ShitaraManaging Exec. Officer and Director of Legal & Intellectual Property DepartmentN/AN/AN/A
Mr. Hiroshi SugitaniManaging Exec. Officer, VP and Head of Sales & Marketing DivisionN/AN/AN/A
Wataru MurataManaging Exec. Officer & Director of HR DepartmentN/AN/AN/A
Dr. Toshifumi Mikayama Ph.D.Sr. Managing Exec. Officer & DirectorN/AN/A1957
Mr. Yutaka OsawaExec. VP & Exec. DirectorN/AN/AN/A
Fumihiko KanaiVP, Head of Production Division & Exec. OfficerN/AN/AN/A
Len PaolilloExec. VP & Chief Commercial Officer of Kyowa kirin, Inc.N/AN/AN/A
Jean-David Rafizadeh-Kabe J.D., M.D.VP, Head Pharmacovigilance of Division & Exec. OfficerN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kyowa Kirin Co., Ltd., a specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Corporate governance

Kyowa Kirin Co., Ltd.’s ISS governance QualityScore as of 1 November 2019 is 2. The pillar scores are Audit: 8; Board: 2; Shareholder rights: 3; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.